REVENUES rose 65 per cent to £18.3m, up from £11.1m last year, at pharma firm Circassia.
The Oxford Science Park-based company specialising in respiratory disease and allergy, announced half-year results to June 30, yesterday.
Sales of asthma drug Niox, were up 19 per cent and under a deal with AstraZeneca, which took a 40 per cent stake in the Oxford firm earlier this year, Circassia markets Turdoza which treats chronic obstructive pulmonary disease.
Circassia’s loss for the period was £34.3m, down from £101.8m.
Chief executive Steve Harris said the firm will continue to add to its 85-staff in Oxford.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel